Abnormal methylation of seven genes and their associations with clinical characteristics in early stage non-small cell lung cancer

Oncology Letters

Volumn 5, Issue 4, 2013, Pages 1211-1218

  Zhao, Yangxing ^a   Zhou, Huafu ^b   Ma, Kelong ^f,g   Sun, Jinfeng ^a   Feng, Xu ^b   Geng, Junfeng ^c   Gu, Jun ^a   Wang, Wei ^a   Zhang, Hongyu ^a   He, Yinghua ^a   Guo, Shicheng ^d   Zhou, Xiaoyu ^e   Yu, Jian ^a   Lin, Qiang ^c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d FUDAN UNIVERSITY   (China)

^e SHANGHAI INSTITUTE OF PLANNED PARENTHOOD RESEARCH   (China)

^f ANHUI MEDICAL UNIVERSITY   (China)

^g ANHUI UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

DNA methylation; Non small cell lung cancer; Smoking; Stage I

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; TRANSCRIPTION FACTOR PITX2; TRANSCRIPTION FACTOR SOX1; VASCULOTROPIN;

ADULT; AGED; ALX1 GENE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DNA ISOLATION; FEMALE; FOXL2 GENE; GENE; GENE EXPRESSION; GENE METHYLATION; GENETIC ASSOCIATION; HPP1 GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METHYLATION; MYF6 GENE; NUCLEOTIDE SEQUENCE; OC2 GENE; PHOX2A GENE; POLYMERASE CHAIN REACTION; RARB GENE; SENSITIVITY AND SPECIFICITY; SIX6 GENE; SMPD3 GENE;

EID: 84874410612     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1161     Document Type: Article

References (16)

1. Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83: 584-594, 2008.
2. Rauch TA, Wang Z, Wu X, Kernstine KH, Riggs AD and Pfeifer GP: DNA methylation biomarkers for lung cancer. Tumour Biol 33: 287-296, 2012.
3. Yu J, Zhu T, Wang Z, et al: A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin Cancer Res 13: 7296-7304, 2007.
4. Feng Q, Hawes SE, Stern JE, et al: DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev 17: 645-654, 2008.
5. Chung JH, Lee HJ, Kim BH, Cho NY and Kang GH: DNA methylation profile during multistage progression of pulmonary adenocarcinomas. Virchows Arch 459: 201-211, 2011.
6. Lin R, Wu C, Chang J, et al: Dysregulation of p53/Sp1 control leads to DNA methyltransferase-1 overexpression in lung cancer. Cancer Res 70: 5807-5817, 2010.
7. Mathews LA, Hurt EM, Zhang X and Farrar WL: Epigenetic regulation of CpG promoter methylation in invasive prostate cancer cells. Mol Cancer 9: 267, 2010.
8. Su HY, Lai HC, Lin YW, Chou YC, Liu CY and Yu MH: An epigenetic marker panel for screening and prognostic prediction of ovarian cancer. Int J Cancer 124: 387-393, 2009.
9. Titulaer MJ, Klooster R, Potman M, et al: SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol 27: 4260-4267, 2009.
10. Benfante R, Antonini RA, Kuster N, et al: The expression of PHOX2A, PHOX2B and of their target gene dopamine-beta-hydroxylase (DbetaH) is not modified by exposure to extremely-low-frequency electromagnetic field (ELF-EMF) in a human neuronal model. Toxicol In Vitro 22: 1489-1495, 2008.
11. Frenzel A, Grespi F, Chmelewskij W and Villunger A: Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis 14: 584-596, 2009.
12. Kelly PN and Strasser A: The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ 18: 1414-1424, 2011.
13. Liu W, Bulgaru A, Haigentz M, Stein CA, Perez-Soler R and Mani S: The BCL2-family of protein ligands as cancer drugs: the next generation of therapeutics. Curr Med Chem Anticancer Agents 3: 217-223, 2003.
14. Vasiljevic N, Wu K, Brentnall AR, et al: Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. Dis Markers 30: 151-161, 2011.
15. Molina R, Alvarez E, Aniel-Quiroga A, et al: Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies. Tumour Biol 32: 13-22, 2011.
16. Ma Z, Tsuchiya N, Yuasa T, et al: Clinical significance of polymorphism and expression of chromogranin a and endothelin-1 in prostate cancer. J Urol 184: 1182-1188, 2010.